Transdermal is a route of administration wherein active ingredients are delivered across the skin for systemic distribution. Examples include transdermal patches used for medicine delivery, and transdermal implants used for medical or aesthetic purposes.
Although the skin is a large and logical target for drug delivery, its basic functions limit its utility for this purpose. The skin functions mainly to protect the body from external insults (e.g. harmful substances and microorganisms) and to contain all body fluids. It must be tough, yet flexible enough to allow for movement. The lipids in our skin serve as poor conductors of electricity and can hence protect us from electrical currents if the need so arises.
There are two important layers to the human skin: (1) the Epidermis and (2) the Dermis. For transdermal delivery, drugs must pass through the two sublayers of the epidermis to reach the microcirculation of the dermis.
The Stratum corneum is the top layer of the skin and varies in thickness from approximately ten to several hundred micrometres, depending on the region of the body. It is composed of layers of dead, flattened keratinocytes surrounded by a lipid matrix, which together act as a brick-and-mortar system that is difficult to penetrate.
The stratum corneum provides the most significant barrier to diffusion. In fact, the stratum corneum is the barrier to approximately 90% of transdermal drug applications. However, nearly all molecules penetrate it to some minimal degree. Below the stratum corneum lies the viable epidermis. This layer is about ten times as thick as the stratum corneum; however, diffusion is much faster here due to the greater degree of hydration in the living cells of the viable epidermis. Below the epidermis lies the dermis, which is approximately one millimeter thick, 100 times the thickness of the stratum corneum. The dermis contains small vessels that distribute drugs into the systemic circulation and to regulate temperature, a system known as the skin's microcirculation.
There are two main pathways by which drugs can cross the skin and reach the systemic circulation. The more direct route is known as the transcellular pathway. By this route, drugs cross the skin by directly passing through both the phospholipids membranes and the cytoplasm of the dead keratinocytes that constitute the stratum corneum.
Although this is the path of shortest distance, the drugs encounter significant resistance to permeation. This is because the drugs must cross the lipophilic membrane of each cell, then the hydrophilic cellular contents containing keratin, and then the phospholipid bilayer of the cell one more time. This series of steps is repeated numerous times to traverse the full thickness of the stratum corneum.
The other more common pathway through the skin is via the intercellular route. Drugs crossing the skin by this route must pass through the small spaces between the cells of the skin, making the route more tortuous. Although the thickness of the stratum corneum is only about 20 µm, the actual diffusional path of most molecules crossing the skin is on the order of 400 µm. The 20-fold increase in the actual path of permeating molecules greatly reduces the rate of drug penetration.
A third pathway to breach the Stratum Corneum layer is via tiny microchannels created by a medical micro-needling device of which there are many brands and variants.  Investigations at the University of Marburg, Germany, using a standard Franz diffusion cell showed that this approach is efficient in enhancing skin penetration ability for lipophilic as well as hydrophilic compounds. The micro-needling approach is also seen as 'the vaccine of the future'.
Devices and formulations
Devices and formulations for transdermally administered substances include:
- Transdermal patch
- Transdermal gel
Pharmacokinetic studies with transdermal glucosamine were conducted in mice in accordance with GLP guidelines. After administration of transdermal glucosamine, maximum plasma concentrations and exposures were observed to be higher than those after oral administration. Likewise, bioavailability of transdermal glucosamine was shown to be high, and the glucosamine was shown to be rapidly and well absorbed, with peak plasma concentration occurring within 2 hours; the half-life of elimination of transdermal glucosamine was about 4 hours. TGC (one version containing 10% w/w glucosamine sulphate salt and another containing 5% w/w glucosamine sulphate salt) is able to increase blood glucosamine concentration significantly (p < 0.01) by greater than 15 folds compared to oral dose of same amount (0.4 g/kg of body weight) in mice. Furthermore, blood glucosamine level could be sustained at a very significant level for up to 7 hrs post-treatment.
Similar transdermal glucosamine profiles were observed with human volunteers (given a single dose of 1.0 g glucosamine sulphate salt). Plasma glucosamine concentration remained relatively high for up to 8 hours post treatment. This provides a good and constant source of glucosamine that could be beneficial to patients suffering from osteoarthritis, as glucosamine is needed in the synthesis of chondroitin sulphate and hyaluronic acid, and these two compounds are depleted in osteoarthritis condition.
- Flynn, G.L. (1996). "Cutaneous and transdermal delivery: Processes and systems of delivery." In Modern Pharmaceutics, Banker, G.S & Rhodes, C.T, eds. New York, NY: Marcel Dekker, 239-299.M
- McCarley, K.D & Bunge, A.L. (2001). "Review of pharmacokinetic models of dermal absorption." J Pharmaceut Sci. 90: 1699–1719.
- Morganti, P., Ruocco, E., Wolf, R., & Ruocco, V. (2001). "Percutaneous absorption and delivery systems." Clin Dermatol. 19: 489-501.
- Hadgraft, J. (2001). "Modulation of the barrier function of the skin." Skin Pharmacol Appl Skin Physiol. 14(1): 72-81.
- Kolli, C.S., Kalluri, H., Desai, N.N. & Banga, A.K. (2007)."Dermaroller as an alternative means to breach the stratum corneum Barrier." College of Pharmacy and Health Sciences, Mercer University, Atlanta GA 30341, USA.
- Verma, D.D. & Fahr, A. "Investigation on the efficacy of a new device for substance deposition into deeper layers of the skin: Dermaroller" Institut für Pharmazeutische Technologie und Biopharmazie, Philipps-Universität Marburg, Marburg, Germany.
- Giudice EL, Campbell JD (2006). "Needle-free vaccine delivery". Adv Drug Deliv Rev 58 (1): 68–89. doi:10.1016/j.addr.2005.12.003. PMID 16564111.
- Lee, C.W., Li, Z., Patel, K., Olobo, J.O., Lee, E.J.D., & Goh L.B. A Phase I Study on the Pharmacokinetic, Safety and Tolerability of Single Dose of Transdermal Glucosamine Cream in Mice and Healthy Human Volunteer Subjects.